Relmada Therapeutics

Relmada Therapeutics is a late-stage biotechnology company dedicated to treating central nervous system (CNS) diseases, with a focus on major depressive disorder (MDD). Relmada's experienced and committed team is devoted to transforming the lives of patients and their families. Relmada’s lead program, REL-1017, is a new chemical entity (NCE) and a novel NMDA receptor (NMDAR) channel blocker that preferentially targets overactive channels while maintaining physiological glutamatergic neurotransmission.